Top Markets
Coin of the day
Bristol-Myers Squibb Company Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

BMY
Hisse Senetlerindeki Sıralama #149
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Hisse Fiyatı
$59.43
Piyasa Değeri
$121.03B
Değişim (1 gün)
0.83%
Değişim (1 yıl)
0.90%
Ülke
US
Ticaret Bristol-Myers Squibb Company (BMY)

Kategori

Bristol-Myers Squibb Company (BMY) için Faaliyet Marjı
March 2026 itibarıyla Faaliyet Marjı TTM: 26.34%
Bristol-Myers Squibb Company şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 26.34%'dir. 2024 yılı sonunda şirketin faaliyet marjı 20.00% idi.
Bristol-Myers Squibb Company için 2000 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
2026 (TTM) 26.34% 0.00%
2025 26.34% 31.70%
2024 20.00% 6.27%
2023 18.82% -6.27%
2022 20.08% -2.38%
2021 20.57% 94.79%
2020 10.56% -57.13%
2019 24.63% -13.09%
2018 28.34% 12.37%
2017 25.22% -5.40%
2016 26.66% 12.11%
2015 23.78% 20.47%
2014 19.74% 3.35%
2013 19.10% -21.14%
2012 24.22% -23.79%
2011 31.78% 0.92%
2010 31.49% 17.32%
2009 26.84% 13.39%
2008 23.67% 21.57%
2007 19.47% 32.00%
2006 14.75% -31.33%
2005 21.48% -11.42%
2004 24.25% 2.71%
2003 23.61% 4.33%
2002 22.63% -14.80%
2001 26.56% -19.17%
2000 32.86% 0.00%
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
45.56% -98.27%
US
23.28% -99.12%
GB
27.17% -98.97%
US
26.72% -98.99%
US
31.24% -98.81%
CH
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.